← All trials
NCT06078384
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2024
- Primary completion
- Dec 1, 2030
- Completion date
- Dec 1, 2031
- First posted
- Oct 11, 2023
- Last posted
- Oct 13, 2023
- Enrollment
- 354
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- UNICANCERLead sponsor
- University of Nice Sophia AntipolisOverall official - principal investigator
- Centre Georges Francois LeclercOverall official - principal investigator
- Centre Leon BerardOverall official - principal investigator
- Institut Gustave RoussyOverall official - principal investigator
- University of ToulouseOverall official - principal investigator
- MerckCollaborator
- SOLTI Breast Cancer Research GroupCollaborator
- Universidad Autonoma de BarcelonaCollaborator
- Institut Gustave RoussyOfficial
- Institut Gustave RoussyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.